Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis.

about

Dystrophin Cardiomyopathies: Clinical Management, Molecular Pathogenesis and Evolution towards Precision Medicine Gene and Cell Therapy for Muscular Dystrophies: Are We Getting There?

P2860

Q58716650-5FFCA0A2-DE47-4D26-A5E8-B84F55E07E98 Q58738445-93F3073D-EB12-4557-8F35-CA66B0942EA8

P2860

Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis.

Item

http://www.wikidata.org/entity/Q55472596

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis.

@en

Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis.

@nl

type

Item

label

Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis.

@en

Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis.

@nl

prefLabel

Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis.

@en

Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis.

@nl

P1476

Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis

@en

P2093

Hirofumi Komaki

http://www.w3.org/2001/XMLSchema#string

Terumi Murakami

http://www.w3.org/2001/XMLSchema#string

Yuko Shimizu-Motohashi

http://www.w3.org/2001/XMLSchema#string

P2860

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: from discovery to clinical trials

Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.

Population frequencies of inherited neuromuscular diseases--a world survey

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

Imputing missing standard deviations in meta-analyses can provide accurate results

The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study.

Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene.

The methodology for developing a prospective meta-analysis in the family planning community.

Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery.

P2888

s13023-018-0834-2

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1186/S13023-018-0834-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

En Kimura

Norio Watanabe

P577

2018-06-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1104597948

http://www.w3.org/2001/XMLSchema#string

P698

29907124

http://www.w3.org/2001/XMLSchema#string

P932

6003096

http://www.w3.org/2001/XMLSchema#string

Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis.

about

P2860

P2860

Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P932